CMS should aspire to an analytically rigorous approach to drug price negotiations

Jun 5

Written By Danielle Bargo

Danielle Bargo

There are more questions than answers when discussing the future of drug pricing

Comments on Negotiation Data Elements and Evidence about Alternative Treatments for the Medicare Drug Price Negotiation Program